Lifesci Capital Has Strong Forecast for Surrozen Q2 Earnings

Key Points

• Lifesci Capital raised its Q2 2026 EPS estimate for Surrozen to ($1.43) from ($2.10), and also lifted its forecasts for Q3, Q4, FY2026, and FY2027.
• Surrozen’s latest quarterly report showed a much larger-than-expected loss of ($11.65) per share, though revenue of $5.0 million beat the consensus estimate.
• Analyst sentiment remains mixed but constructive overall, with HC Wainwright reaffirming a Buy rating and a $44 price target while MarketBeat’s consensus stands at Moderate Buy.

Surrozen, Inc. (NASDAQ:SRZN - Free Report) - Investment analysts at Lifesci Capital increased their Q2 2026 earnings per share (EPS) estimates for shares of Surrozen in a note issued to investors on Thursday, May 7th. Lifesci Capital analyst P. Dolezal now expects that the company will earn ($1.43) per share for the quarter, up from their prior forecast of ($2.10). The consensus estimate for Surrozen's current full-year earnings is ($7.20) per share. Lifesci Capital also issued estimates for Surrozen's Q3 2026 earnings at ($1.48) EPS, Q4 2026 earnings at ($1.10) EPS, FY2026 earnings at ($7.62) EPS and FY2027 earnings at ($6.65) EPS.

Surrozen (NASDAQ:SRZN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($11.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($10.56). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 4,810.50%.The business had revenue of $5.00 million during the quarter, compared to the consensus estimate of $4.00 million.

A number of other equities analysts have also issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $40.00 price target on shares of Surrozen in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research note on Tuesday, April 21st. Wall Street Zen raised Surrozen from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. HC Wainwright reaffirmed a "buy" rating and set a $44.00 price target (up from $36.00) on shares of Surrozen in a research note on Thursday. Finally, TD Cowen started coverage on Surrozen in a research note on Tuesday, April 21st. They set a "buy" rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $42.00.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $28.96 on Monday. The stock has a fifty day moving average price of $28.50 and a two-hundred day moving average price of $22.38. The firm has a market cap of $332.75 million, a P/E ratio of -0.77 and a beta of 0.59. Surrozen has a 1 year low of $5.90 and a 1 year high of $35.00.

Insider Buying and Selling

In other news, CEO Craig C. Parker sold 4,524 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $33.33, for a total transaction of $150,784.92. Following the completion of the sale, the chief executive officer owned 16,553 shares in the company, valued at approximately $551,711.49. This represents a 21.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tcg Crossover Gp Ii, Llc bought 106,658 shares of Surrozen stock in a transaction dated Tuesday, March 24th. The stock was acquired at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the acquisition, the insider directly owned 736,554 shares of the company's stock, valued at approximately $18,185,518.26. This represents a 16.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 189,734 shares of company stock worth $4,677,729 and have sold 8,144 shares worth $271,440. Insiders own 31.74% of the company's stock.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of Surrozen in the second quarter valued at about $536,000. Vanguard Group Inc. grew its position in shares of Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company's stock valued at $3,433,000 after purchasing an additional 47,468 shares during the last quarter. Acuta Capital Partners LLC grew its position in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company's stock valued at $2,299,000 after purchasing an additional 8,415 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen in the third quarter valued at about $889,000. 66.57% of the stock is owned by institutional investors and hedge funds.

More Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Lifesci Capital raised its estimates for Surrozen’s Q2, Q3, and Q4 2026 earnings, signaling slightly better near-term expectations than before. Source report
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $44 price target on SRZN, suggesting some analysts still see meaningful upside from current levels. Source report
• Neutral Sentiment: A head-to-head comparison article with Rigel Pharmaceuticals was published, but it does not appear to include a direct catalyst for Surrozen’s stock movement. Rigel Pharmaceuticals versus Surrozen Head to Head Comparison
• Negative Sentiment: HC Wainwright cut its FY2026, FY2027, FY2028, FY2029, and FY2030 EPS estimates, pointing to continued expectations for significant losses over the next several years. Source report
• Negative Sentiment: The company’s recent earnings release showed a far larger-than-expected quarterly loss, which likely remains a drag on investor sentiment. Source report

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.